Memory-protective drug for Alzheimer’s on the horizon

Scientists have come up with a new drug which could prevent patients with features of Alzheimer’s disease (AD) from suffering memory loss and brain damage.

This drug, called BPN14770, stops toxic effects resulting from the presence of beta-amyloid, the hallmark protein that forms the characteristic plaques in AD. By inhibiting a key enzyme called phosphodiesterase 4D (PDE4D), it helps prevent memory loss, preserve dendritic number and length, and promote the formation of synaptic proteins that enhance or conserve normal connections between neurons. It also increases the levels of an important molecule called cAMP which is essential to memory.

Earlier studies have shown that dementia is not seen in a quarter of healthy elderly patients with AD even at 80 years. This could mean that there are compensatory mechanisms that help the brain cells to work around the plaques, and thus prevent the occurrence of memory loss even and disease progression.

The new drug seeks to trigger these protective mechanisms in order to keep nerves and brain cells healthy, staving off dementia. If successful, it could also be used to treat the incurable Fragile X syndrome, schizophrenia and certain developmental disabilities.

Alzheimer
Alzheimer's disease: Pathological Tau protein (red-orange) phosphorylation (yellow) leads to disintegration of microtubuli and aggregation to neurofibrillary tangles (orange) in a neuron axon. Image Credit: Juan Gaertner / Shutterstock

How does the drug work?

BPN14770, which was developed by a collaborative effort between scientists at the University at Buffalo and Tetra Therapeutics, appears to use an array of biological pathways to preserve an intact memory, prevent nerve damage and preserve a normal biochemistry within the brain. It blocks the binding of the PDE4D to its substrate or receptor, which is called allosteric inhibition. PDE4D is involved in the breakdown of the cell messenger molecule called cAMP (cyclic adenosine monophosphate).

The drug also increases the level of cAMP that is important in learning, forming memories, brain inflammation and traumatic brain injury. It produces various changes in the body such as cell division, cell change, migration and death. These could, obviously, cause changes in brain structure as well. However, cAMP also exerts a positive effect on memory. By increasing cAMP levels in the brain, BPN14770 protects the organ against amyloid-induced toxicity.

Animal studies show that BPN14770 could help stabilize synaptic connections which are seriously affected in Fragile X, and lost in AD patients with memory loss. Earlier phase 1 studies carried out in healthy older people showed it helps improve working memory. This is the type of memory that underlies the immediate remembering of things and thus of task performance, among others.

It is now being tested in Phase 2 trials for early AD as well as Fragile X syndrome. Researcher James O’ Donnell says, “BPN14770 works by a novel mechanism to increase cyclic AMP signaling in the brain, which has been shown to improve memory.” Another researcher, Ying Xu, says, “Our new research suggests that BPN14770 may be capable of activating multiple biological mechanisms that protect the brain from memory deficits, neuronal damage and biochemical impairments.”

The study was published on September 5, 2019, in the Journal of Pharmacology and Experimental Therapeutics.

Journal reference:

Protection from amyloid β peptide-induced memory, biochemical and morphological deficits by a phosphodiesterase-4D (PDE4D) allosteric inhibitor. Su-Ying Cui, Ming-Xin Yang, Yong-He Zhang, Victor Zheng, Han-Ting Zhang, Mark E. Gurney, Ying Xu and James M. O'Donnell. Journal of Pharmacology and Experimental Therapeutics. September 5, 2019, jpet.119.259986; DOI: https://doi.org/10.1124/jpet.119.259986, http://jpet.aspetjournals.org/content/early/2019/09/05/jpet.119.259986

Dr. Liji Thomas

Written by

Dr. Liji Thomas

Dr. Liji Thomas is an OB-GYN, who graduated from the Government Medical College, University of Calicut, Kerala, in 2001. Liji practiced as a full-time consultant in obstetrics/gynecology in a private hospital for a few years following her graduation. She has counseled hundreds of patients facing issues from pregnancy-related problems and infertility, and has been in charge of over 2,000 deliveries, striving always to achieve a normal delivery rather than operative.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, Liji. (2019, September 10). Memory-protective drug for Alzheimer’s on the horizon. News-Medical. Retrieved on November 18, 2019 from https://www.news-medical.net/news/20190910/Memory-protective-drug-for-Alzheimere28099s-on-the-horizon.aspx.

  • MLA

    Thomas, Liji. "Memory-protective drug for Alzheimer’s on the horizon". News-Medical. 18 November 2019. <https://www.news-medical.net/news/20190910/Memory-protective-drug-for-Alzheimere28099s-on-the-horizon.aspx>.

  • Chicago

    Thomas, Liji. "Memory-protective drug for Alzheimer’s on the horizon". News-Medical. https://www.news-medical.net/news/20190910/Memory-protective-drug-for-Alzheimere28099s-on-the-horizon.aspx. (accessed November 18, 2019).

  • Harvard

    Thomas, Liji. 2019. Memory-protective drug for Alzheimer’s on the horizon. News-Medical, viewed 18 November 2019, https://www.news-medical.net/news/20190910/Memory-protective-drug-for-Alzheimere28099s-on-the-horizon.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
CCNY researchers receive two U.S. patents for brain cancer-detecting innovation